Patents by Inventor Lone Fjord-Larsen

Lone Fjord-Larsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic use of a growth factor, METRNL
    Patent number: 10034918
    Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: July 31, 2018
    Assignee: Hoba Therapeutics ApS
    Inventors: Jesper R. Jorgensen, Lone Fjord-Larsen, Lars Ulrik Wahlberg, Nuno Miguel Gomes Andrade, Teit E. Johansen
  • Therapeutic Use of a Growth Factor, METRNL
    Publication number: 20170333526
    Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects.
    Type: Application
    Filed: May 8, 2017
    Publication date: November 23, 2017
    Inventors: Jesper R. Jorgensen, Lone Fjord-Larsen, Lars Ulrik Wahlberg, Nuno Miguel Gomes Andrade, Teit E. Johansen
  • Therapeutic use of a growth factor, METRNL
    Patent number: 9675669
    Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: June 13, 2017
    Assignee: HOBA THERAPEUTICS APS
    Inventors: Jesper R. Jorgensen, Lone Fjord-Larsen, Lars Ulrik Wahlberg, Nuno Miguel Gomes Andrade, Teit E. Johansen
  • THERAPEUTIC USE OF A GROWTH FACTOR, METRNL
    Publication number: 20160045564
    Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects.
    Type: Application
    Filed: May 26, 2015
    Publication date: February 18, 2016
    Inventors: Jesper R. Jorgensen, Lone Fjord-Larsen, Lars Ulrik Wahlberg, Nuno Miguel Gomes Andrade, Teit E. Johansen
  • Therapeutic use of a growth factor, METRNL
    Patent number: 9068015
    Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: June 30, 2015
    Assignee: NsGene A/S
    Inventors: Jesper Roland Jorgensen, Lone Fjord-Larsen, Lars Ulrik Wahlberg, Nuno Miguel Gomes Andrade, Teit E. Johansen
  • THERAPEUTIC USE OF A GROWTH FACTOR, METRNL
    Publication number: 20130267464
    Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects.
    Type: Application
    Filed: December 14, 2012
    Publication date: October 10, 2013
    Applicant: NsGene A/S
    Inventors: Jesper R. Jorgensen, Lone Fjord-Larsen, Lars Ulrik Wahlberg, Nuno Miguel Gomes Andrade, Teit E. Johansen
  • Therapeutic use of a growth factor, METRNL
    Patent number: 8334264
    Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects.
    Type: Grant
    Filed: July 7, 2009
    Date of Patent: December 18, 2012
    Assignee: NsGenee A/S
    Inventors: Jesper Roland Jørgensen, Lone Fjord-Larsen, Lars Ulrik Wahlberg, Nuno Miguel Gomes Andrade, Teit E. Johansen
  • THERAPEUTIC USE OF A GROWTH FACTOR, METRNL
    Publication number: 20110112035
    Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects.
    Type: Application
    Filed: July 7, 2009
    Publication date: May 12, 2011
    Inventors: Jesper Roland Jørgensen, Lone Fjord-Larsen, Lars Ulrik Wahlberg, Nuno Miguel Gomes Andrade, Teit E. Johansen